Korro Bio, Inc. (KRRO) Financial Statements
Korro Bio, Inc. (KRRO) reported trailing twelve-month revenue of $2.4M (down 62.1% year on year) and net income of -$106.6M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$68.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KRROKorro Bio, Inc.Follow KRRO — free
—
Price chart with a free account
- Market cap
- 176.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 28.9 | 37.0 | 14.1 | 2.3 | 6.4 | 2.4 | |
| Gross profit | 12.9 | — | — | — | — | — | |
| Research & development | 18.8 | 37.4 | 60.9 | 63.6 | 65.6 | 51.3 | |
| Operating income | -20.7 | -27.6 | -84.0 | -91.9 | -121.9 | -110.2 | |
| Pre-tax income | -18.7 | -26.5 | -84.7 | -83.4 | -116.6 | -105.8 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.1 | 0.6 | 0.8 | |
| Net income | -18.7 | -26.5 | -84.7 | -83.6 | -117.3 | -106.6 | |
| Diluted EPS ($) | -2.29 | -0.82 | -2.47 | -9.37 | -12.48 | -6.05 | |
| Diluted shares (mn) | — | — | — | 8.9 | 9.4 | — |
USD millions · SEC XBRL
Korro Bio, Inc. — questions
- What is Korro Bio, Inc.'s revenue?
- $2.4M over the twelve months to 2026-06-30, down 62.1% year on year, from its 10-Q and 10-K filings.
- What is Korro Bio, Inc.'s net income?
- -$106.6M over the twelve months to 2026-06-30.
- What is Korro Bio, Inc.'s free cash flow?
- -$68.3M over the twelve months to 2026-06-30.
- What are Korro Bio, Inc.'s diluted earnings per share?
- $-6.05 over the twelve months to 2026-06-30.
Every figure on this page comes from Korro Bio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.